Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset ...

Merus (MRUS) keeps catching attention as its shares post impressive gains over the past month, rising around 46%. Recent investor interest appears closely linked to ongoing optimism around the company ...

Merus N.V. (NASDAQ:MRUS), a clinical-stage biopharmaceutical company specializing in targeted oncology antibody assets, has recently been the subject of significant market attention due to its pending ...

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Merus (MRUS – Research Report) on November 3 and set a price target of $41.00. Andrew Berens has given his Buy rating to Merus’s stock ...

Needham analyst Ami Fadia maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $85.00. Ami Fadia’s rating is based on several strategic developments within Merus ...

Learn more about whether Merus N.V. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, entered into an agreement in which Merus has exclusively licensed to Partner ...

Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a ...